ZymoGenetics competitors

Zippia score 4.2

ZymoGenetics main competitors are Exelixis, Gilead Sciences, and Vertex Pharmaceuticals.

Competitor Summary. See how ZymoGenetics compares to its main competitors:

Merck has the most employees (74,000).
Employees at Exelixis earn more than most of the competitors, with an average yearly salary of $108,978.
The oldest company is Merck, founded in 1891.

Work at ZymoGenetics?

Share your experience

ZymoGenetics vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
ZymoGenetics	1981	4.2	Seattle, WA	1	$27.0M	200
Regeneron	1988	4.9	Tarrytown, NY	7	$14.2B	9,123
Sarepta Therapeutics	1980	4.8	Cambridge, MA	2	$1.9B	840
Sanofi Genzyme	1981	4.8	Cambridge, MA	1	$4.6B	12,000
Exelixis	1994	4.9	Alameda, CA	1	$2.2B	484
Amgen	1980	4.8	Thousand Oaks, CA	9	$33.4B	22,000
Seagen	1997	4.7	Bothell, WA	3	$2.0B	900
Gilead Sciences	1987	4.5	Foster City, CA	9	$28.8B	11,800
Neurocrine Biosciences	1992	4.7	San Diego, CA	1	$2.4B	400
Vertex Pharmaceuticals	1989	4.6	Boston, MA	5	$11.0B	3,400
Merck	1891	4.6	Kenilworth, NJ	31	$64.2B	74,000
Alnylam Pharmaceuticals	2002	4.8	Cambridge, MA	2	$2.2B	1,323
Arena Pharmaceuticals	1997	4.8	San Diego, CA	1	$54,000	194
Ambrx	2003	4.6	San Diego, CA	1	$7.4M	80
ABC Laboratories	1968	4.2	Columbia, MD	1	$72.0M	3,000
XBiotech	2005	4.5	Austin, TX	1	$4.0M	56
Protein Sciences	1983	4.4	Meriden, CT	1	$23.9M	150
Zyomyx	1998	4.0	Fremont, MO	1	$840,000	5
Agenus	1994	4.5	Lexington, MA	2	$103.0M	294
Genetics Institute	1980	3.9	Cambridge, MA	1	$7.5M	500
Cellerant Therapeutics	2003	3.9	San Carlos, CA	1	$3.8M	7

Rate how well ZymoGenetics differentiates itself from its competitors.

ZymoGenetics salaries vs competitors

Among ZymoGenetics competitors, employees at Exelixis earn the most with an average yearly salary of $108,978.

Compare ZymoGenetics salaries vs competitors

Company	Average salary	Hourly salary	Salary score
ZymoGenetics	$90,249	$43.39	-
Regeneron	$85,589	$41.15	-
Sarepta Therapeutics	$94,985	$45.67	-
Sanofi Genzyme	$84,495	$40.62	-
Exelixis	$108,978	$52.39	-
Amgen	$93,349	$44.88	-

Compare ZymoGenetics job title salaries vs competitors

Company	Highest salary	Hourly salary
ZymoGenetics	$88,111	$42.36
Exelixis	$92,672	$44.55
Amgen	$90,533	$43.53
Regeneron	$89,788	$43.17
Agenus	$88,943	$42.76
Sarepta Therapeutics	$86,852	$41.76
Sanofi Genzyme	$86,785	$41.72
Vertex Pharmaceuticals	$85,938	$41.32
Merck	$83,799	$40.29
Alnylam Pharmaceuticals	$77,994	$37.50
Gilead Sciences	$76,146	$36.61
Protein Sciences	$75,235	$36.17
Arena Pharmaceuticals	$75,172	$36.14
Seagen	$74,996	$36.06
XBiotech	$74,624	$35.88
Cellerant Therapeutics	$74,615	$35.87
Ambrx	$73,477	$35.33
ABC Laboratories	$71,936	$34.58
Zyomyx	$71,687	$34.46
Genetics Institute	$70,641	$33.96

Do you work at ZymoGenetics?

Does ZymoGenetics effectively differentiate itself from competitors?

ZymoGenetics jobs

ZymoGenetics demographics vs competitors

Compare gender at ZymoGenetics vs competitors

Job title	Male	Female
Agenus	48%	52%
Alnylam Pharmaceuticals	49%	51%
Arena Pharmaceuticals	55%	45%
Gilead Sciences	56%	44%
Amgen	57%	43%
ZymoGenetics	-	-

Male

Female

100%

75%

50%

25%

ZymoGenetics

Amgen

Gilead Sciences

Arena Pharmaceuticals

Alnylam Pharmaceuticals

Agenus

25%

50%

75%

100%

Compare race at ZymoGenetics vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Agenus	76%	10%	6%	6%	2%	8.3
Alnylam Pharmaceuticals	59%	14%	5%	16%	6%	9.1
Amgen	49%	24%	7%	15%	5%	9.7
Arena Pharmaceuticals	44%	20%	8%	24%	5%	9.6
Gilead Sciences	44%	20%	8%	23%	6%	9.8
Merck	56%	16%	10%	14%	4%	9.8

ZymoGenetics and similar companies CEOs

CEOBio

Garo H. Armen Ph.d

Agenus

Garo H. Armen is a Turkish-born American businessman of Armenian descent. He is the co-founder of Agenus, Inc. and the founder of the Children of Armenia Fund (COAF), a non-profit organization which focuses on reducing poverty, through “education, healthcare, community and economic development”.

Yvonne L. Greenstreet

Alnylam Pharmaceuticals

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

Robert A. Bradway

Amgen

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Michael M. Morrissey Ph.d

Exelixis

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

Daniel O’Day

Gilead Sciences

Robert M. Davis

Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Douglas S. Ingram

Sarepta Therapeutics

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.

Roger D. Dansey

Seagen

Reshma Kewalramani M.d

Vertex Pharmaceuticals

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

John Simard

XBiotech

John Simard is a Chairman/President/CEO/Founder at XBiotech USA Inc, VP/Founder at MANNKIND CORP, and Board Member at MANNKIND CORP. He attended University of Toronto.